EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia

Janisha Patel, Xueliang Gao iD, Haizhen Wang iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24087201 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Janisha Patel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA. Hauptthemen laut MEDLINE: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Receptors, Chimeric Antigen, Antibodies, Bispecific. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current therapies for T-cell acute leukemia are based on risk stratification and have greatly improved the survival rate for patients, but mortality rates remain high owing to relapsed disease, therapy resistance, or treatment-related toxicities/infection. Patients with relapsed disease continue to have poor outcomes. In the past few years, newer agents have been investigated to optimize upfront therapies for higher-risk patients in the hopes of decreasing relapse rates. This review summarizes the progress of chemo/targeted therapies using Nelarabine/Bortezomib/CDK4/6 inhibitors for T-ALL in clinical trials and novel strategies to target NOTCH-induced T-ALL. We also outline immunotherapy clinical trials using monoclonal/bispecific T-cell engaging antibodies, anti-PD1/anti-PDL1 checkpoint inhibitors, and CAR-T for T-ALL therapy. Overall, pre-clinical studies and clinical trials showed that applying monoclonal antibodies or CAR-T for relapsed/refractory T-ALL therapy is promising. The combination of target therapy and immunotherapy may be a novel strategy for T-ALL treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor T-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAntibodies, BispecificHumansImmunotherapyAntibodies, MonoclonalT-LymphocytesImmunotherapy, Adoptive

Stichwörter der Autor:innen

CAR-T therapyT-cell acute lymphoblastic leukemiaclinical trialsimmunotherapyrefractoryrelapse

Substanzen

Receptors, Chimeric AntigenAntibodies, MonoclonalAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Department of Pediatric Hematology/Oncology, Medical University of South Carolina-Shawn Jenkins Children's Hospital, Charleston, SC 29425, USA.

ORCID-Profile: Xueliang Gao, Haizhen Wang

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • Bristol-Myers Squibb Melanoma Research Alliance Young Investigator Award
  • American Cancer Society Institutional Research Grant
  • National Institute of General Medical Sciences Pilot Project

Zitieren

APA

Patel, J., Gao, X., & Wang, H. (2023). An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087201

Vancouver

Patel J, Gao X, Wang H. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087201

BibTeX
@article{Patel2023,
  author = {Patel, Janisha and Gao, Xueliang and Wang, Haizhen},
  title = {An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24087201}
}
Kostenlos starten →